Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2737
http://purl.obolibrary.org/obo/NCIT_C2737
|
|---|---|
| Preferred Name | Vandetanib |
| Definitions |
An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. |
|---|---|
| prefLabel | Vandetanib
|
| label | Vandetanib
|
| CHEBI_ID | CHEBI:49960
|
| PDQ_Closed_Trial_Search_ID | 269177
|
| code | C2737
|
| Has_Target | |
| prefixIRI | NCIT:C2737
|
| in_subset |
See more
See less
|
| Display_Name | Vandetanib
|
| Preferred_Name | Vandetanib
|
| FDA_UNII_Code | YO460OQ37K
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C22H24BrFN4O2
|
| Maps_To | Vandetanib
|
| CAS_Registry | 443913-73-3
|
| NCI_Drug_Dictionary_ID | 269177
|
| Legacy Concept Name | ZD-6474
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of lung cancer and other types of cancer. It may block the growth and spread of tumor cells and prevent the growth of new blood vessels that tumors need to grow. Vandetanib is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 269177
|
| Accepted_Therapeutic_Use_For | Thyroid Cancer
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1384659
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |